Apellis Pharmaceuticals, Inc.(APLS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

Apellis Pharmaceuticals, Inc. (APLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores APLS at 62.5/100 on a 32-signal composite quality model, placing it at rank #709 of 2,961 stocks — the top 25% of the AI-ranked universe. APLS scores in the top quartile across revenue growth (92.8), balance sheet strength (91.9), profitability (75.4). Areas of concern include free cash flow (36.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Apellis Pharmaceuticals, Inc. reports quarterly revenue of $268.3M, net income of $18.7M, an operating margin of 9.9%. Top institutional holders of APLS by reported 13-F value include BlackRock, Avoro Capital Advisors, MORGAN STANLEY, based on the most recent SEC filings. APLS trades on the Nasdaq exchange and files with the SEC under CIK 1492422. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apellis Pharmaceuticals, Inc. directly from SEC EDGAR.